The rivalry between two of the biggest names in weight-loss medicine has spilled into court, with drug giant Novo Nordisk suing its competitor Eli Lilly. The dispute centers on how the companies' blockbuster treatments are being presented to the public, and it puts a spotlight on the fierce competition in a fast-growing corner of the pharmaceutical market.
At the heart of the lawsuit is Eli Lilly's direct-to-consumer advertising for its treatments Zepbound and Mounjaro. Novo Nordisk claims those advertisements portray its own products, Wegovy and Ozempic, in a less favorable light, drawing a comparison between the rival drugs that Novo argues is unfair.
According to the suit, the problem lies in the information the advertising relies on. Novo Nordisk contends that the comparison is built on outdated information taken from a study, meaning the picture presented to consumers does not reflect the most current data on how the treatments stack up against one another.
Novo Nordisk is pressing for the advertising to be pulled quickly. The company has said it will seek a court order to block the advertisements if Eli Lilly does not voluntarily take them down within two days, signaling that it wants the disputed marketing removed while the broader legal fight plays out.
Eli Lilly, for its part, is not backing down. Responding to the lawsuit, the company said it will defend against the claims vigorously, rejecting the idea that its advertising crossed a line. It framed its position as a firm defense of how it presented its treatments to the public.
Lilly also defended the substance of the material at the center of the case. The company described the information it publicized as a gold standard for comparing medicines, arguing that the basis for its advertising was sound rather than misleading, directly countering Novo's characterization of it as outdated.
The clash underscores just how high the stakes have become in the market for weight-loss and diabetes treatments, where Novo's Wegovy and Ozempic and Lilly's Zepbound and Mounjaro are among the most closely watched products. With both sides digging in, the fight over the advertising is now set to be settled in the courts.